From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.
|Articles|July 11, 2022
The Mainstream Patient: July 11
Author(s)Kaitlyn Bader, Associate Editor
This week's edition of the Mainstream Patient features stories about dermaplaning tools, pregnancy-safe sunscreens, botox, and more.
Advertisement
In this week’s edition, Self reviews dollar store pregnancy tests and InStyle talks dermaplaning tools. Cosmopolitan lists the best pregnancy-safe sunscreens and Glamour discusses botox. Elle determines the best early Amazon Prime Day beauty deals and Allure praises indigenous-owned beauty brands.
Dollar Store Pregnancy Tests Are Reliable, Cheap, and Worth Stocking Up on Right Now
The 6 Best At-Home Dermaplaning Tools for Smooth, Fuzz-Free Skin
13 Best Pregnancy-Safe Sunscreens for Ultra-Gentle Protection
Women Are Still Hiding Botox From Their Husbands. Why?
The 18 Best Early Prime Day Beauty Deals To Shop Right Now
7 Indigenous-Owned Beauty Brands Making Their Mark on the Industry
Advertisement
Related to this article
Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.
The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.
Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria
3
Improving Early Identification and Escalation of HS
4
Dupilumab and Catch-Up Growth in Children With Severe Atopic Dermatitis
5